Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Science Committee

Executive Summary

FDA's Pharmaceutical Science Advisory Committee will meet Oct. 6 to discuss risk management for complex pharmaceuticals, bioequivalence for highly variable drugs, current thinking on nanotechnology, implementation of definitions for topical dosage forms and current strategies and future directions for the Critical Path initiative. On Oct. 5, the committee will hear presentations on quality-by-design by the Pharmaceutical Research & Manufacturers of America and Generic Pharmaceutical Association. [Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS047520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel